Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Galderma describes new apoptosis-inducing antitumor agents

Oct. 21, 1999

Orphan Medical completes licensing agreement with Pierre Fabre

Oct. 21, 1999

Antisense gene therapy technology available for licensing from NIH

Oct. 20, 1999

U.S. and Israeli researchers disclose angiogenic and antiangiogenic endostatin-derived peptides

Oct. 20, 1999

Structurally novel PARP inhibitors for cancer, neurodegenerative disorders designed at Pierre Fabre

Oct. 20, 1999

Novel double-prodrug quinones as effective treatment of solid tumors

Oct. 20, 1999

Mechanism of herbicide analogue XK-469's antitumor activity pinpointed

Oct. 20, 1999

Onyx and Warner-Lambert collaborate on development of anticancer virus products

Oct. 20, 1999

DuPont granted patent rights to Duke's new antiestrogens

Oct. 19, 1999

Therion Biologics and NCI initiate phase II trial of novel melanoma vaccines

Oct. 19, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 14, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026